Abstract:956 Background: Most patients with metastatic cancer will eventually succumb to their disease despite an initial response to chemotherapy. To enhance treatment efficacy, chemotherapy has been combined with cytokines, often with disappointing results. Another example is “Immunocentric Chemoimmunotherapy,” with primary focus placed on immunotherapy, with chemotherapy as an immunomodulator. We have developed a novel strategy termed “Chemocentric Chemoimmunotherapy,” where chemotherapy plays the central role, with immunotherapy as a chemosensitizer. The rationale is the ability of activated T cells to secret multiple cytokines, which may regulate gene expression in tumor cells. Methods: Human CD4+ T cells were isolated and activated with anti-CD3/anti-CD28 mAb. Tumor cells were presensitized with activated CD4+ T cells (aCD4), followed by treatment with various chemotherapy. Cell viability and apoptosis were determined. Transwell system was used to assess contribution of cell-cell contact vs. soluble factor(s). Results: Presensitization of A375 melanoma cells with aCD4 synergistically enhanced the cytotoxic effects of chemotherapy. Cell viability (CV) was 75% (+SD: 0.11) and 90% (+SD: 0.26) after treatment with temozolomide (TMZ) alone or with aCD4 alone, respectively. However, CV in the experimental group was 7% (+SD: 0.02). This synergistic effect was also observed with other melanoma cell lines, nonmelanoma tumor cell lines, and other chemotherapy. Two breast, one prostate, and one colon cancer cell lines were presensitized with aCD4, followed by treatment with paclitaxel, carboplatin, or 5-FU. Consistent synergistic effect was seen in each case. For example, CV in MDA-MB-231 breast cancer cells treated with paclitaxel alone or aCD4 alone was 93% (+SD: 0.16) and 52% (+SD: 0.10), respectively. However, CV in the experimental group was 8% (+SD: 0.18). The same synergism was observed in DU145 prostate cancer cell line treated with carboplatin. CV in the carboplatin-treated group and aCD4-treated group was 100% (+ SD: 0.13) and 75% (+SD: 0.14), respectively; while CV of the experimental group was 5% (+SD: 0.19). The rate of apoptosis in cells treated with both TMZ and aCD4 was 20 times higher than in cells treated with only TMZ or aCD4. This effect was due entirely to soluble factors. The aCD4 was found to secret large amounts of multiple cytokines. Preliminary data showed that IFN-γ might not be the major cytokine mediating the observed effect. Conclusion: Presensitization of tumor cells with aCD4 synergistically enhanced the cytotoxic effect of chemotherapy. This effect was completely dependent on soluble factors, most likely cytokines. We are in the process of elucidating the mechanisms underlying this dramatic synergy.

Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy

Anthracyclines Potentiate Anti-Tumor Immunity: A New Opportunity for Chemoimmunotherapy.

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment

Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades

Immunological aspects of cancer chemotherapy

Abstract P53: Inhibition of STING/Galectin-9 Axis Sensitize Anthracyclines Treatment And Induce Anti-tumor Immunity

Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?

Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy

Enhancing Cancer Chemo‐Immunotherapy: Innovative Approaches for Overcoming Immunosuppression by Functional Nanomaterials

Recent Advances in Engineered Materials for Immunotherapy‐Involved Combination Cancer Therapy

Activated Cd4(+) T Cells Dramatically Enhance Chemotherapeutic Tumor Responses in Vitro and in Vivo

Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity

Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment

"Chemocentric" Chemoimmunotherapy: Presensitization of Tumor Cells with Activated Cd4+T Cells Synergistically Enhances the Cytotoxic Effect of Chemotherapy

Boosting antitumor immunity in breast cancers: Potential of adjuvants, drugs, and nanocarriers

Development of Platinum Complexes for Tumor Chemoimmunotherapy

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment

Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges